All AbMole products are for research use only, cannot be used for human consumption.
Vandortuzumab vedotin (DSTP 3086S) is an antibody-drug-conjugate to target prostate cancer.
| CAS Number | 1471985-92-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
[1] Anthony Markham. Drugs. Tisotumab Vedotin: First Approval
[2] Emma D Deeks. Drugs. Disitamab Vedotin: First Approval
[3] Emma D Deeks. Drugs. Polatuzumab Vedotin: First Global Approval
[4] Carrie Van Der Weyden, et al. Expert Rev Hematol. Brentuximab vedotin in T-cell lymphoma
| Related Antibody-Drug Conjugates (ADCs) Products |
|---|
| Inotuzumab MMAE
Inotuzumab MMAE is an anti-CD22 antibody-drug conjugate (ADC). |
| Ulocuplumab-MMAE
Ulocuplumab-MMAE is an antibody-drug conjugate (ADC). |
| Lorvotuzumab-MMAE
Lorvotuzumab-MMAE is an antibody-drug conjugate (ADC). |
| Anetumab-MMAE
Anetumab-MMAE is an antibody-drug conjugate (ADC). |
| Praluzatamab-MMAE
Praluzatamab-MMAE is an antibody-drug conjugate (ADC). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
